These findings may also, in part, explain the differences in infection outcomes between ANSWER and ATTIRE, in that albumin infusions may improve binding capacity in these outpatients as they most likely had less albumin dysfunction, with median MELD score 12–13, and alcohol abstinence at trial entry in ANSWER compared with an MELD of 20 and most patients with alcohol-induced cirrhosis in ATTIRE. This evidence concerns the gene ALB and infection.